Renocel inj
Reading File
Searching the Web
Renocel injection composition uses
Finding Sources
Reading Web Page
Renocel injection uses dosage side effects mechanism
Finding Sources
Searching the Web
Renocel epoetin alfa injection dosage side effects contraindications India
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Here is a complete overview of Renocel Injection:
Renocel Injection (Erythropoietin Alfa / Epoetin Alfa)
Composition
Renocel is a recombinant human erythropoietin alfa (Epoetin alfa) - a synthetic form of the naturally occurring hormone erythropoietin (EPO). Available strengths: 2000 IU, 3000 IU, 4000 IU, and 10000 IU per injection vial.
Manufacturer: Cipla Ltd. (India)
Mechanism of Action
Erythropoietin is produced primarily by the kidneys in response to tissue hypoxia. It acts on erythroid progenitor cells in the bone marrow, stimulating their proliferation and differentiation into mature red blood cells (RBCs). In chronic kidney disease (CKD), failing kidneys cannot produce adequate erythropoietin - the dominant mechanism behind renal anemia. Recombinant erythropoietin (Renocel) replaces this deficiency.
- Guyton and Hall Textbook of Medical Physiology: "The most important cause of this anemia is decreased renal secretion of erythropoietin, which stimulates the bone marrow to produce red blood cells."
- Goldman-Cecil Medicine: "The major pathogenetic factor in the anemia of chronic kidney disease is erythropoietin deficiency."
Indications (Uses)
| Indication | Details |
|---|---|
| Anemia of Chronic Kidney Disease (CKD) | Pre-dialysis and dialysis patients; primary use |
| Chemotherapy-induced anemia | In cancer patients receiving myelosuppressive chemotherapy |
| HIV/Zidovudine-associated anemia | In patients on zidovudine therapy for HIV |
| Pre-surgical anemia reduction | To reduce allogeneic blood transfusion need before elective non-cardiac surgery |
Treatment is initiated when hemoglobin falls below 9 g/dL, with a target of 9-11 g/dL to avoid complications of overcorrection (Goldman-Cecil Medicine).
Dosage & Administration
| Route | Details |
|---|---|
| Subcutaneous (SC) | Preferred for non-dialysis and cancer patients |
| Intravenous (IV) | Used in hemodialysis patients |
Typical starting doses:
- CKD (non-dialysis): 50-100 IU/kg SC, 3x/week
- Hemodialysis: 50-300 IU/kg IV, 3x/week
- Chemotherapy-induced anemia: 150 IU/kg SC, 3x/week (or 40,000 IU once weekly)
Doses are titrated based on hemoglobin response. Iron stores must be adequate for response (transferrin saturation and ferritin should be checked).
Contraindications
- Hypersensitivity to epoetin alfa, albumin, or any excipient
- Uncontrolled hypertension
- Pure red cell aplasia (PRCA) due to prior ESA therapy
- Non-chemotherapy-associated anemia in cancer patients
- Planned cardiac/vascular surgery (relative)
- Use of multi-dose vials in children or pregnant women
Warnings & Precautions
Black Box Warning (ESA class):
- Increased risk of death, MI, stroke, venous thromboembolism, and tumor progression/recurrence when hemoglobin is targeted above 11 g/dL
- Do NOT use to correct hemoglobin to normal or near-normal levels
Other important warnings:
- Hypertension: Can worsen or precipitate; monitor BP closely
- Seizures: Risk increases especially during initiation; avoid in patients with uncontrolled seizures
- Thrombosis: DVT, PE, and vascular access thrombosis in dialysis patients
- Pure Red Cell Aplasia (PRCA): Rare but serious; caused by antibodies to erythropoietin - stop therapy immediately if suspected
- Tumor progression: ESAs may promote angiogenesis in some cancers
Side Effects
| Common | Serious |
|---|---|
| Headache, nausea, vomiting | Hypertensive crisis |
| Fever, body aches, flu-like symptoms | Thromboembolism (DVT, PE, MI, stroke) |
| Injection site pain/irritation | Pure red cell aplasia |
| Dizziness | Seizures |
| Elevated blood pressure | Serious allergic reactions / anaphylaxis |
Drug Interactions
- Cyclosporine: Epoetin increases cyclosporine clearance; monitor levels
- Ramipril / ACE inhibitors: May blunt the erythropoietic response
- Thalidomide: Increased thromboembolism risk when combined
Special Populations
| Population | Guidance |
|---|---|
| Pregnancy | Use only if clearly needed; teratogenicity not fully established |
| Breastfeeding | Caution advised |
| Pediatrics | Multi-dose vials (with benzyl alcohol) are contraindicated |
| Geriatric | Standard dosing; monitor closely for cardiovascular events |
Key Clinical Pearl
Adequate iron supplementation is essential for Renocel to work - functional iron deficiency is the most common reason for poor response to ESA therapy. Check ferritin and transferrin saturation before and during therapy; supplement iron (preferably IV in dialysis patients) if levels are suboptimal.
Bottom line: Renocel is a biosimilar/branded erythropoiesis-stimulating agent (ESA) used primarily for renal anemia. It is effective but must be used with hemoglobin targets in mind (9-11 g/dL) to minimize the serious cardiovascular and oncologic risks associated with the drug class.
This is a shared conversation. Sign in to Orris to start your own chat.